Evaluation of 1<sup>st</sup> WHO anti-malaria reference reagent for competition ELISA harmonisation and development of ADAMSEL analytical platform.
Khatri B. et al, (2025), Biologicals : journal of the International Association of Biological Standardization
MetE: a promising protective antigen for tuberculosis vaccine development
Almujri SS. et al, (2025), Frontiers in Immunology, 16
Acute Plasmodium yoelii 17XNL Infection During BCG Vaccination Limits T Cell Responses and Mycobacterial Growth Inhibition.
Tangie E. et al, (2025), Immunology
Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCG
Marshall JL. et al, (2025), Nature Communications, 16
Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development.
Siegal EZ. et al, (2025), NPJ vaccines, 10
Incidence of diabetes mellitus following hospitalisation for COVID‐19 in the United Kingdom: A prospective observational study
Tyrer F. et al, (2025), Diabetes, Obesity and Metabolism, 27, 767 - 776
Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study.
Gharibzadeh S. et al, (2025), EClinicalMedicine, 79
Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis.
De Voss CJ. et al, (2025), Frontiers in immunology, 16
Strong immune responses and robust protection following a novel protein in adjuvant tuberculosis vaccine candidate.
Korompis M. et al, (2025), Scientific reports, 15
Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal route
Peralta Alvarez MP. et al, (2024), Vaccine, 42, 126444 - 126444
MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates
Peralta-Álvarez MP. et al, (2024), npj Vaccines, 9
A dose escalation study to evaluate the safety of an aerosol BCG infection in previously BCG-vaccinated healthy human UK adults
Fredsgaard-Jones T. et al, (2024), Frontiers in Immunology, 15
Mtb-Specific HLA-E-Restricted T Cells Are Induced during Mtb Infection but Not after BCG Administration in Non-Human Primates and Humans
Voogd L. et al, (2024), Vaccines, 12, 1129 - 1129
Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK
Taquet M. et al, (2024), The Lancet Psychiatry, 11, 696 - 708
Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patients.
Ongarj J. et al, (2024), Tuberculosis (Edinburgh, Scotland), 148
Randomised, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route.
Audran R. et al, (2024), The Journal of infection, 89
Review of Current Tuberculosis Human Infection Studies for Use in Accelerating Tuberculosis Vaccine Development: A Meeting Report.
Balasingam S. et al, (2024), The Journal of infectious diseases, 230, e457 - e464
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial
Satti I. et al, (2024), The Lancet Infectious Diseases, 24, 909 - 921